Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Carolina Ayelen IsnardiOsvaldo L CerdaMargarita LandiLeonel CrucesEmilce Edith SchneebergerClaudia Calle MontoroMaría Agustina AlfaroBrian M RoldánAndrea B Gómez VaraPamela GiorgisRoberto Alejandro EzquerMaría G Crespo RochaCamila R Reyes GómezMária de Los Ángeles CorreaMarcos G RosemffetVirginia Carrizo AbarzaSantiago Catalan PelletMiguel PerandonesCecilia ReimundesYesica LongueiraGabriela TurkMaria Florencia QuirogaNatalia L LauferRosana Maris QuintanaMaría Celina de la VegaNicolás KreplakMarina PifanoPablo MaidGuillermo J Pons-EstelGustavo CiteraPublished in: The Journal of rheumatology (2022)
In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.